A network meta-analysis of efficacy of mesenchymal stem cells from different sources in treatment of premature ovarian failure animal models

doi:10.12307/2025.533

Abstract

Abstract: OBJECTIVE: Premature ovarian failure has manifested a trend of younger, and stem cell therapy has been progressively implemented in clinical practice in recent years. Nevertheless, given the extensive range of sources and variegated existence of stem cells in diverse tissues, certain disparities prevail in their biological characteristics and functions. In this paper, the therapeutic efficacies of dissimilar sources of mesenchymal stem cells on animal models of premature ovarian failure were contrasted, with the aim of providing a basis for the clinical application of stem cells.
METHODS: The animal model experiments of mesenchymal stem cell therapy for premature ovarian failure were retrieved from PubMed, The Cochrane Library, and EMbase, as well as Chinese databases such as CNKI, WanFang, VIP, and China Biomedical Literature Service. The search period extended from the inception to December 31, 2023. Two researchers independently screened the literature, extracted and analyzed the data. The quality of the included studies was evaluated by means of the SYRCLE animal experiment bias risk assessment table. Main outcome measures: Follicle stimulating hormone, estradiol, luteinizing hormone, the quantity of follicles at all levels. Secondary outcome measure: Pregnancy rate. Network meta-analysis, mapping, and tabulation were executed using Stata 17.0 software after assessing the risk of bias in the included studies.
RESULTS: Totally 24 animal experiment studies were incorporated, and the overall quality of the literature was mediocre, encompassing 7 distinct sources of mesenchymal stem cells. They were umbilical cord-derived mesenchymal stem cells, menstrual blood-derived mesenchymal stem cells, placenta-derived mesenchymal stem cells, human cord blood-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, adipose-derived mesenchymal stem cells, and amnio-derived mesenchymal stem cells. The network meta-analysis demonstrated that (1) in contrast to the blank group, mesenchymal stem cells from various sources were effective in enhancing the pregnancy rate and estradiol, reducing follicle-stimulating hormone and luteinizing hormone, augmenting the number of follicles at all levels, and diminishing the number of atretic follicles. (2) According to the area map under the cumulative sequencing curve, the three stem cells with the most prominent efficacy in improving estradiol levels were umbilical cord-derived mesenchymal stem cells (72.7%) > adipose-derived mesenchymal stem cells (72.6%) > menstrual blood-derived mesenchymal stem cells (71.7%). (3) The three kinds of stem cells with the highest efficacy in reducing follicle-stimulating hormone levels were the adipose-derived mesenchymal stem cells (96.3%) > human cord blood-derived mesenchymal stem cells (65.4%) > umbilical cord-derived mesenchymal stem cells (63.9%). (4) The three kinds of stem cells with the highest efficacy in reducing luteinizing hormone levels were adipose-derived mesenchymal stem cells (100.0%) > umbilical cord-derived mesenchymal stem cells (51.6%) > human cord blood-derived mesenchymal stem cells (46.8%). (5) The top three kinds of stem cells for increasing the number of primordial follicles were human cord blood-derived mesenchymal stem cells (76.3%) > umbilical cord-derived mesenchymal stem cells (75.5%) > menstrual blood-derived mesenchymal stem cells (57.5%). (6) The top three kinds of stem cells for increasing the number of primary follicles were umbilical cord-derived mesenchymal stem cells (75.3%) > adipose-derived mesenchymal stem cells (53.0%) > the placenta-derived mesenchymal stem cells (51.7%). (7) The top three kinds of stem cells for increasing the number of secondary follicles were adipose-derived mesenchymal stem cells (76.1%) > menstrual blood-derived mesenchymal stem cells (66.8%) > umbilical cord-derived mesenchymal stem cells (66.5%). (8) The top three kinds of stem cells in reducing the number of atretic follicles were adipose-derived mesenchymal stem cells (99.9%) > bone marrow-derived mesenchymal stem cells (68.1%) > umbilical cord-derived mesenchymal stem cells (53.4%).
CONCLUSION: (1) For animal models of premature ovarian failure, the results of the network meta-analysis disclosed that various stem cell transplantation treatments were preponderant over the blank or placebo group to varying extents, and the efficacies were comparable. (2) The results indicated that umbilical cord-derived mesenchymal stem cells were the most frequently utilized and adipose-derived mesenchymal stem cells were the most potent. More high-quality experimental study data are requisite in the future for further validation.

Key words: stem cells, premature ovarian failure, animal experiments, network meta-analysis, follicular number, estradiol, follicle-stimulating hormone, luteinizing hormone

CLC Number:

Li Zhe, Li Ping, Zhang Chao, Guo Guangling. A network meta-analysis of efficacy of mesenchymal stem cells from different sources in treatment of premature ovarian failure animal models[J]. Chinese Journal of Tissue Engineering Research, 2025, 29(36): 7898-7908.

Figures/Tables 15

References

[1] ALI I, PADHIAR AA, WANG T, et al. Stem cell-based therapeutic strategies for premature ovarian insufficiency and infertility: a focus on aging. Cells. 2022;11(23):3713.
[2] KIRSHENBAUM M, ORVIETO R. Premature ovarian insufﬁciency (POI) and autoimmunity-an update appraisal. J Assist Reprod Genet. 2019;36:2207-2215.
[3] SHEIKHANSARI G, AGHEBATI-MALEKI L, NOURI M, et al. Current approaches for the treatment of premature ovarian failure with stem cell therapy. Biomed Pharmacother. 2018;102:254-262.
[4] VOLAREVIC V, BOJIC S, NURKOVIC J, et al. Stem cells as new agents for the treatment of infertility: current and future perspectives and challenges. BioMed Res. Int. 2014;2014:507234.
[5] ZHENG Q, FU X, JIANG J, et al. Umbilical cord mesenchymal stem cell transplantation prevents chemotherapy-induced ovarian failure via the NGF/TrkA pathway in rats. Biomed Res Int. 2019; 2019:6539294.
[6] LI Z, ZHANG M, TIAN Y, et al. Mesenchymal stem cells in premature ovarian insufficiency: mechanisms and prospects. Front Cell Dev Biol. 2021;9:718192.
[7] 陈匡阳,马彬,王亚楠,等.SYRCLE动物实验偏倚风险评估工具简介[J].中国循证医学杂志, 2014,14(10):1281-1285.
[8] 文进,李幼平.Meta分析中效应尺度指标的选择[J].中国循证医学杂志,2007;7(8):606-613.
[9] JIE H, JINXIANG W, YE L, et al. Effects of umbilical cord mesenchymal stem cells on expression of CYR61, FSH and AMH in mice with premature ovarian failure. Cell Mol Biol (Noisy-le-grand). 2022;67(4):358-366.
[10] JALALIE L, REZAEE MA, REZAIE MJ, et al. Human umbilical cord mesenchymal stem cells improve morphometric and histopathologic changes of cyclophosphamide-injured ovarian follicles in mouse model of premature ovarian failure. Acta Histochem. 2021;123(1):151658.
[11] DENG T, HE J, YAO Q, et al. Human umbilical cord mesenchymal stem cells improve ovarian function in chemotherapy-induced premature ovarian failure mice through inhibiting apoptosis and inflammation via a paracrine mechanism. Reprod Sci. 2021;28(6):1718-1732.
[12] 赵淑颖,郭广玲,董斯睿,等.脐带间充质干细胞移植对卵巢早衰模型小鼠卵巢功能的影响[J].生物医学工程与临床,2022,26(1):15-21.
[13] SHEN J, CAO D, SUN JL. Ability of human umbilical cord mesenchymal stem cells to repair chemotherapy-induced premature ovarian failure. World J Stem Cells. 2020;12(4):277-287.
[14] YANG Y, LEI L, WANG S, et al. Transplantation of umbilical cord-derived mesenchymal stem cells on a collagen scaffold improves ovarian function in a premature ovarian failure model of mice. In Vitro Cell Dev Biol Anim. 2019;55(4):302-311.
[15] 付霞霏,何援利.脐带间充质干细胞移植对免疫性卵巢早衰的影响[J].广东医学,2013,34(23): 3535-3538.
[16] PARK HS, CHUGH RM, ELSHAROUD A, et al. Safety of intraovarian injection of human mesenchymal stem cells in a premature ovarian insufficiency mouse model. Cell Transplant. 2021;30:963689720988502.
[17] 彭静,肖娜,程腊梅.骨髓来源间充质干细胞对卵巢早衰小鼠的修复作用[J].中南大学学报(医学版),2018,43(1):7-13.
[18] 张莹莹,殷慧群,倪丰,等.骨髓间充质干细胞移植在卵巢早衰小鼠卵巢功能重建中应用[J].安徽农业大学学报,2017,44(1):44-49.
[19] BADAWY A, SOBH MA, AHDY M, et al. Bone marrow mesenchymal stem cell repair of cyclophosphamide-induced ovarian insufficiency in a mouse model. Int J Womens Health. 2017;9:441-447.
[20] 陈京京,殷慧群,汪存利,等.骨髓间充质干细胞移植在卵巢早衰小鼠卵巢及生育功能重建中的作用[J].安徽医科大学学报,2017,52(11):1611-1615.
[21] 范雪,王爱娟,张云,等.骨髓间充质干细胞移植对卵巢早衰模型小鼠卵巢功能的影响[J].中国老年学杂志,2016,36(21):5222-5224.
[22] 王毅峰,宋文广,刘淑霞.人脐血单个核细胞移植治疗裸鼠放射性卵巢早衰[J].中国组织工程研究,2016,20(36):5398-5404.
[23] DANG J, JIN Z, LIU X, et al. Human cord blood mononuclear cell transplantation for the treatment of premature ovarian failure in nude mice. Int J Clin Exp Med. 2015;8(3):4122-4127.
[24] 包秀芳,孙萍.人脐血单个核细胞对半乳糖卵巢早衰小鼠卵巢功能的影响[J].中国医药生物技术,2015,10(5):424-427.
[25] LIU T, HUANG Y, ZHANG J, et al. Transplantation of human menstrual blood stem cells to treat premature ovarian failure in mouse model. Stem Cells Dev. 2014;23(13):1548-1557.
[26] 徐焱焱.经血间充质干细胞通过IGF-1/AKT/FOXO3a信号通路改善化疗源小鼠卵巢早衰的实验研究[D].银川:宁夏医科大学,2020.
[27] 王臻,黄康榕,王月玲,等.经血来源干细胞移植在小鼠卵巢早衰模型中的定位分布[J].西安交通大学学报(医学版),2017,38(6):803-808.
[28] 孙芳,韦伟.GnRH激动剂和经血源性干细胞联合治疗对小鼠卵巢功能的影响[J].南方医科大学学报,2021,41(12):1850-1856.
[29] 赵达,包利利,王晓黎,等.脂肪间充质干细胞对卵巢早衰小鼠卵巢内分泌功能及颗粒细胞凋亡的影响[J].医学研究杂志,2023,52(8):173-177.
[30] 白塔吉,马玉珍.脂肪间充质干细胞对小鼠化疗性卵巢功能不全的治疗作用及机制研究[J].中国妇产科临床杂志,2022,23(6):617-621.
[31] YIN N, ZHAO W, LUO Q, et al. Restoring ovarian function with human placenta-derived mesenchymal stem cells in autoimmune-induced premature ovarian failure mice mediated by treg cells and associated cytokines. Reprod Sci. 2018; 25(7):1073-1082.
[32] 蒋春艳.人羊膜间充质干细胞修复卵巢功能的实验研究[D].南京:南京医科大学,2014.
[33] 唐华均,李成志.卵巢早衰的病因及治疗进展[J].重庆医学,2018,47(13):1777-1780.
[34] CORDTS EB, CHRISTOFOLINI DM, DOS SANTOS AA, et al. Genetic aspects of premature ovarian faillure:a literature review. Arch Gynecol Obstet. 2011;283(3):635-643.
[35] 邵华.中药联合激素替代疗法治疗卵巢早衰的研究进展[J].中国城乡企业卫生,2022,37(5):13-15.
[36] 陈醒,周应芳,白文佩.绝经期激素替代治疗的相关肿瘤风险研究进展[J].国际妇产科学杂志,2016,43(5):489-492,496.
[37] 刘紫君,常惠,王宇,等.干细胞治疗生殖系统疾病的研究进展[J].生殖医学杂志,2021, 30(6):836-841.
[38] KISIEL AH, MCDUFFEE LA, MASAOUD E, et al. Isolation, characterization, and in vitro proliferation of canine mesenchymal stem cells derived from bone marrow, adipose tissue, muscle, and periosteum. Am J Vet Res. 2012;73(8):1305-1317.
[39] 赵淑颖,郭广玲,刘晨晨,等.干细胞移植治疗卵巢早衰:基于13篇动物实验的Meta分析[J].中国组织工程研究,2022,26(25):4084-4092.
[40] 李萍,郭广玲,董斯睿,等.脐带间充质干细胞移植治疗卵巢早衰有效性动物实验的Meta分析[J].中国循证医学杂志,2022,22(9): 1041-1047.
[41] 刘荣霞,杨炳,余丽梅,等.不同来源间充质干细胞治疗卵巢早衰的作用及机制研究进展[J].山东医药,2018,58(40):106-110.
[42] LEVY O, KUAI R, SIREN EMJ, et al. Shattering barriers toward clinically meaningful MSC therapies. Sci Adv. 2020;6:eaba6884.
[43] LU X, CUI J, CUI L, et al. The effects of human umbilical cord-derived mesenchymal stem cell transplantation on endometrial receptivity are associated with Th1/Th2 balance change and uNK cell expression of uterine in autoimmune premature ovarian failure mice. Stem Cell Res Ther. 2019;10(1):214.
[44] ZHENG Q, FU X, JIANG J, et al., Umbilical cord mesenchymal stem cell transplantation prevents chemotherapy-induced ovarian failure via the NGF/TrkA pathway in rats. Biomed Res Int. 2019; 2019:6539294.
[45] 陈英霞,王换换,戴晓宇,等. GDF-9转染的脂肪间充质干细胞治疗化疗性卵巢早衰大鼠[J].现代妇产科进展,2017,26(11):822-828.
[46] TAKEHARA Y, YABUUCHI A, EZOE K, et al., The restorative effects of adipose-derived mesenchymal stem cells on damaged ovarian function. Lab Invest. 2013;93(2):181-193.
[47] 阴春霞,曲红光,曹阳,等.脂肪干细胞对顺铂所致卵巢早衰大鼠细胞因子的影响[J].中国妇幼保健,2016,31(24):5480-5482.
[48] UZBAS E, MAY ID, PARISI AM, et al. Molecular physiognomies and applications of adipose-derived stem cells. Stem Cell Rev Rep. 2015;2:298-308.
[49] 许思娟.月经血源性间充质干细胞在女性生殖系统疾病中的应用进展[J].实用妇产科杂志, 2021,37(5):354-357.
[50] 闫忠蕊.Gadd45b在MB-MSCs修复表柔比星致GCs损伤机制中的实验研究[D].天津:天津医科大学,2019.
[51] ELFAYOMY AK, ALMASRY SM, EL-TARHOUNY SA, et al. Human umbilical cord blood-mesenchymal stem cells transplantation renovates the ovarian surface epithelium in a rat model of premature ovarian failure: possible direct and indirect effects. Tissue Cell. 2016;48(4):370-382.
[52] FU YX, JI J, SHAN F, et al. Human mesenchymal stem cell treatment of premature ovarian failure: new challenges and opportunities. Stem Cell Res Ther. 2021;12:161.
[53] MOHAMED S, SHALABY S, BRAKTA S, et al. Umbilical cord blood mesenchymal stem cells as an infertility treatment for chemotherapy induced premature ovarian insufficiency. Biomedicines. 2019;7(1):7.
[54] ELFAYOMY KA, ALMASRY MS, EL-TARHOUNY AS, et al. Human umbilical cord blood-mesenchymal stem cells transplantation renovates the ovarian surface epithelium in a rat model of premature ovarian failure: possible direct and indirect effects. Tissue and Cell. 2016;48(4):370-382.
[55] 侯巧妮,马会明,相丽,等.人胎盘间充质干细胞移植对化疗所致卵巢早衰大鼠卵巢功能的影响[J].山东大学学报(医学版),2019,57(2):52-60.
[56] 尹娜.人胎盘间充质干细胞移植能够修复自身免疫性卵巢早衰小鼠卵巢功能[D].滨州:滨州医学院,2018.
[57] 李永丽,陈冬梅,徐仙,等.胎盘间充质干细胞培养液对卵巢早衰模型大鼠卵巢BCL-2表达的影响[J].宁夏医学杂志,2020,42(8):673-676, 672.
[58] SEOK J, PARK H, CHOI HJ, et al. Placenta-derived mesenchymal stem cells restore the ovary function in an ovariectomized rat model via an antioxidant effect. Antioxidants. 2020;9(7):591.
[59] LAI D, WANG F, YAO X, et al. Human endometrial mesenchymal stem cells restore ovarian function through improving the renewal of germline stem cells in a mouse model of premature ovarian failure. J Transl. Med. 2015;13:155.
[60] 余丽梅,刘荣霞,张小雨,等.人羊膜间充质干细胞治疗卵巢早衰的作用和机制[J].中国药理学与毒理学杂志, 2019,33(10):919-920.